Harel Insurance Investments & Financial Services Ltd. Buys New Stake in Pfizer Inc. $PFE

Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Pfizer Inc. (NYSE:PFE) during the 1st quarter, Holdings Channel.com reports. The fund purchased 24,000 shares of the biopharmaceutical company’s stock, valued at approximately $674,000.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Horizon Financial Services LLC boosted its position in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer in the 4th quarter valued at $26,000. YANKCOM Partnership purchased a new stake in Pfizer during the fourth quarter worth $28,000. HFM Investment Advisors LLC grew its position in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Finally, Evolution Wealth Management Inc. increased its position in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 566 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer received FDA approval for a Padcev plus Keytruda regimen in muscle-invasive bladder cancer, expanding use of the combination as a new treatment option and supporting the company’s oncology growth story. Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen
• Positive Sentiment: Analyst commentary remains constructive on Pfizer’s valuation, with some recent coverage suggesting the stock may still offer upside versus Wall Street targets despite recent weakness. Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?
• Neutral Sentiment: Market commentary also says Pfizer’s shares are below key moving averages, reflecting a cautious technical setup as investors weigh fading COVID revenue against pipeline growth, acquisitions, and dividend support. Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?
• Neutral Sentiment: Pfizer also faces a new patent dispute, as Arbutus Biopharma filed international lawsuits over lipid nanoparticle technology used in mRNA COVID-19 vaccines. The case adds legal overhang, though the financial impact is still uncertain. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
• Negative Sentiment: Pfizer suspended sales of Premarin vaginal cream in India due to supply challenges, which could weigh on near-term international product sales and signals execution issues in the supply chain. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Analysts Set New Price Targets

A number of research firms have recently commented on PFE. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a research note on Tuesday, June 9th. JPMorgan Chase & Co. cut their target price on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. Wolfe Research reiterated an “underperform” rating and set a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Finally, UBS Group reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $28.50.

Pfizer Trading Up 1.3%

PFE opened at $25.13 on Friday. The stock has a market capitalization of $143.24 billion, a PE ratio of 19.19 and a beta of 0.35. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The business’s 50 day moving average price is $25.22 and its 200 day moving average price is $26.18.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter last year, the firm earned $0.92 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.